Ram Kamineni - Krystal Biotech Senior Operations
| KRYS Stock | USD 164.42 1.26 0.76% |
Executive
Ram Kamineni is Senior Operations of Krystal Biotech
| Address | 2100 Wharton Street, Pittsburgh, PA, United States, 15203 |
| Phone | 412 586 5830 |
| Web | https://www.krystalbio.com |
Krystal Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0497) % which means that it has lost $0.0497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0887 %, meaning that it created $0.0887 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Krystal Biotech's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.13) in 2024. At this time, Krystal Biotech's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 630.6 M in 2024, whereas Other Assets are likely to drop slightly above 354 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Steven JD | AVROBIO | 62 | |
| Robert Sweeney | Ocean Biomedical | 59 | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| Emily Hill | PTC Therapeutics | 44 | |
| Candice Masse | Elevation Oncology | N/A | |
| Esq CPA | Ocean Biomedical | 59 | |
| Hege SollieZetlmayer | PTC Therapeutics | N/A | |
| Pierre MS | PTC Therapeutics | 38 | |
| Robert Yang | Elevation Oncology | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| Kirsten Dupuis | AVROBIO | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| Scott Gottesman | AVROBIO | N/A | |
| Jane Baj | PTC Therapeutics | N/A | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| Christine Utter | PTC Therapeutics | 46 | |
| Andreas Kouri | AVROBIO | N/A | |
Management Performance
| Return On Equity | 0.0887 | ||||
| Return On Asset | -0.0497 |
Krystal Biotech Leadership Team
Elected by the shareholders, the Krystal Biotech's board of directors comprises two types of representatives: Krystal Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Krystal. The board's role is to monitor Krystal Biotech's management team and ensure that shareholders' interests are well served. Krystal Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Krystal Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Wilson, Head Marketing | ||
| David Chien, Senior Development | ||
| Hubert MD, Senior Development | ||
| Gloria Lin, Accounting Mang | ||
| Kathryn Romano, Executive Officer | ||
| Katherine Tuminello, HR Mang | ||
| Suma Krishnan, President Founder | ||
| Jennifer McDonough, Analytics Access | ||
| MS MBA, Chairman, Founder | ||
| John Karakkal, Vice Marketing | ||
| Ram Kamineni, Senior Operations | ||
| David Glynn, Commercial Counsel | ||
| John Thomas, General Secretary | ||
| Laurent Goux, Senior Europe | ||
| Andreas Orth, Ex Officer | ||
| Josh Suskin, Director Operations | ||
| Meg Dodge, Vice Communications |
Krystal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Krystal Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0887 | ||||
| Return On Asset | -0.0497 | ||||
| Profit Margin | 0.60 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 4.17 B | ||||
| Shares Outstanding | 28.56 M | ||||
| Shares Owned By Insiders | 12.75 % | ||||
| Shares Owned By Institutions | 95.08 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Earning | (6.36) X |
Pair Trading with Krystal Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Krystal Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Krystal Stock
Moving against Krystal Stock
| 0.68 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.39 | PTN | Palatin Technologies Fiscal Year End 26th of September 2024 | PairCorr |
| 0.31 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to Krystal Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Krystal Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Krystal Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Krystal Biotech to buy it.
The correlation of Krystal Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Krystal Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Krystal Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Krystal Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.